Survival of European children and young adults with cancer diagnosed 1995–2002

Gatta, Gemma; Zigon, Giulia; Capocaccia, Riccardo; Coebergh, Jan Willem; Désandes, Emmanuel; Kaatsch, Peter; Pastore, Guido; Peris-Bonet, Rafael; Stiller, Charles

doi:10.1016/j.ejca.2008.11.042

Cited by 451 publications

(350 citation statements)

References 18 publications

Supporting

Mentioning

325

Contrasting

Unclassified

Order By: Relevance

“…Across Europe survival rates improved for children diagnosed with CNS tumours and in particular CNS embryonal tumours between 1995 and 2002 (30). Other studies have also shown a general improvement in survival for childhood CNS tumours over the last [20][21][22][23][24][25][26][27][28][29][30] years identifying improvements in CNS embryonal tumour survival specifically (3,16,19,30,31).…”

Section: Discussionmentioning

confidence: 99%

“…Other studies have also shown a general improvement in survival for childhood CNS tumours over the last [20][21][22][23][24][25][26][27][28][29][30] years identifying improvements in CNS embryonal tumour survival specifically (3,16,19,30,31). TYA, aged 16-24 years, from Yorkshire showed a significant increase in survival from medulloblastoma and CNS PNET combined between 1990 and 2009 (32).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and survival of children and young people with central nervous system embryonal tumours in the North of England, 1990–2013

Fairley

Picton

McNally

et al. 2016

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Incidence and survival of children and young people with central nervous system embryonal tumours in the North of England, 1990–2013

Fairley

Picton

McNally

et al. 2016

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Major improvements in the treatment of childhood malignancies have led to increased survival, with 5-year survival rates reaching .80% in Europe (1). As survival has greatly improved, the effect of late adverse effects after treatment for childhood cancer has increased correspondingly (2)(3)(4).…”

Section: Introductionmentioning

confidence: 99%

Renal Dysfunction and Elevated Blood Pressure in Long-Term Childhood Cancer Survivors

Knijnenburg¹,

Jaspers²,

Pal³

et al. 2012

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryBackground and objectives Little is known about renal function and blood pressure (BP) in long-term childhood cancer survivors. This cross-sectional study evaluated prevalence of these outcomes and associated risk factors in long-term childhood cancer survivors at their first visit to a specialized outpatient clinic.Design, Setting, Participants, & Measurements Estimated GFR; percentages of patients with albuminuria, hypomagnesemia, and hypophosphatemia; and BP were assessed in 1442 survivors $5 years after diagnosis. Multivariable logistic regression analyses were used to estimate effect of chemotherapy, nephrectomy, and radiation therapy on the different outcomes.Results At a median age of 19.3 years (interquartile range, 15.6-24.5 years), 28.1% of all survivors had at least one renal adverse effect or elevated BP. The median time since cancer diagnosis was 12.1 years (interquartile range, 7.8-17.5 years). High BP and albuminuria were most prevalent, at 14.8% and 14.5%, respectively. Sixty-two survivors (4.5%) had an estimated GFR ,90 ml/min per 1.73 m 2 . Survivors who had undergone nephrectomy had the highest risk for diminished renal function (odds ratio, 8.6; 95% confidence interval [CI], 3.4-21.4). Combined radiation therapy and nephrectomy increased the odds of having elevated BP (odds ratio, 4.92; 95% CI, 2.63-9.19), as did male sex, higher body mass index, and longer time since cancer treatment.Conclusion Almost 30% of survivors had renal adverse effects or high BP. Therefore, monitoring of renal function in high-risk groups and BP in all survivors may help clinicians detect health problems at an early stage and initiate timely therapy to prevent additional damage.

show abstract

“…Thus, we excluded patients hierarchically if they [1] had significant congenital heart disease or a history of cardiac dysfunction prior to their cancer diagnosis; [2] developed cardiac dysfunction during therapy or in the first year after completing therapy, characterized by overt CHF or two consecutive echocardiographic studies with reduced EF or SF in the absence of clinical symptoms; [3] died prior to 1 year after the completion of their cancer therapy; or [4] were transferred to another pediatric institution or were discharged from care at age 18 years, prior to being 1 year from the conclusion of therapy. We then assessed the frequency of abnormal surveillance echocardiograms performed more than 1 year from the conclusion of therapy in the eligible cohort and categorized them according to the 12 risk categories identified in the COG LTFU guidelines.…”

mentioning

confidence: 99%

Echocardiographic surveillance for asymptomatic late‐onset anthracycline cardiomyopathy in childhood cancer survivors

Abosoudah

Greenberg

Ness

et al. 2011

Pediatric Blood & Cancer

View full text Add to dashboard Cite

BackgroundThe optimal frequency of echocardiographic surveillance in asymptomatic childhood cancer survivors exposed to anthracyclines has not been established. We evaluated the effectiveness of performing surveillance echocardiograms according to the Children's Oncology Group's (COG) Long‐Term Follow‐Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers in survivors ≥1 year from concluding therapy.MethodsWe reviewed all children treated at our institution with anthracycline chemotherapy from 1995 to 2003. We assessed the frequency of abnormal echocardiograms according to risk groups defined in the COG guidelines, and evaluated the risk factors for an abnormal echocardiogram using Cox proportional hazards modeling.ResultsAt least one echocardiogram was completed by 469/603 (77.8%) eligible survivors. Mean diagnosis age was 7.7 (SD = 4.6) years. Mean cumulative doxorubicin‐equivalent dose was 205 mg/m2 (SD = 115). Survivors completed 1,013 echocardiograms (median = 2, range = 1–10) beyond 1 year after concluding therapy. Seventy‐nine (16.8%) survivors had an abnormal echocardiogram at a median of 2.9 years (range 0.01–9.8) from 1 year after concluding therapy. Anthracycline dose >300 mg/m2 (hazard ratio [HR] 3.00; 95% CI 1.51–5.98), age 1–4 years at treatment (HR 1.89; 95% CI 1.08–3.31) and radiation to a field involving the heart (HR 1.73; 95% CI 1.08–2.76) predicted an increased risk of an abnormal echocardiogram; however, even survivors in the lower COG risk groups demonstrated abnormalities.ConclusionPeriodic echocardiographic surveillance in childhood cancer survivors can yield abnormalities that require further evaluation. Abnormalities may become evident as early as 1 year after the conclusion of therapy and can impact even those survivors considered to be at low risk. Pediatr Blood Cancer 2011; 57: 467–472. © 2011 Wiley‐Liss, Inc.

show abstract

Survival of European children and young adults with cancer diagnosed 1995–2002

Cited by 451 publications

References 18 publications

Incidence and survival of children and young people with central nervous system embryonal tumours in the North of England, 1990–2013

Incidence and survival of children and young people with central nervous system embryonal tumours in the North of England, 1990–2013

Renal Dysfunction and Elevated Blood Pressure in Long-Term Childhood Cancer Survivors

Echocardiographic surveillance for asymptomatic late‐onset anthracycline cardiomyopathy in childhood cancer survivors

Contact Info

Product

Resources

About